- JP-listed companies
- Delta-Fly Pharma, Inc.
- Balance sheet
Delta-Fly Pharma, Inc. (4598) Balance sheet
Market cap
¥2.1B
P/E ratio
-1.2x
Delta-Fly Pharma develops cancer treatments using a unique "modular drug discovery" approach that builds new drugs from existing cancer-fighting compounds.
| 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Cash and cash equivalents | - | 781 | 3,508 | 1,944 | 2,089 | 1,268 | 844 | 1,417 | 339 |
| Total cash & short-term investments | - | 781 | 3,508 | 1,944 | 2,089 | 1,268 | 844 | 1,417 | 339 |
| Total current assets | - | 832 | 3,532 | 2,116 | 2,115 | 1,281 | 866 | 1,433 | 395 |
| Property, plant and equipment, net | - | 31 | 32 | 43 | 42 | 40 | 39 | 38 | 37 |
| Total non-current assets | - | 32 | 35 | 46 | 46 | 44 | 41 | 41 | 40 |
| Total assets | - | 864 | 3,567 | 2,162 | 2,161 | 1,324 | 907 | 1,474 | 434 |
| Long-term debt, current | - | 7 | 7 | 6 | - | - | - | - | - |
| Total current liabilities | - | 29 | 57 | 106 | 82 | 91 | 116 | 241 | 157 |
| Total non-current liabilities | - | 13 | 6 | - | - | - | - | - | - |
| Total liabilities | - | 42 | 63 | 106 | 82 | 91 | 116 | 241 | 157 |
| Retained earnings | - | -1,393 | -2,066 | -3,622 | -4,485 | -5,452 | -6,781 | -8,210 | -9,931 |
| Stockholders' equity | 769 | 822 | 3,504 | 2,056 | 2,079 | 1,233 | 791 | 1,233 | 278 |